Altimmune to test obesity drug for alcohol use disorder and related health conditions
Portfolio Pulse from
Altimmune plans to test its experimental obesity drug, pemvidutide, for treating alcohol use disorder and alcohol-associated liver disease.
March 13, 2025 | 9:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Altimmune is expanding the potential applications of its obesity drug, pemvidutide, to include treatment for alcohol use disorder and alcohol-associated liver disease.
The announcement of testing pemvidutide for additional health conditions could increase investor interest and optimism about Altimmune's future prospects, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100